Pressmeddelande -
Galenica AB’s Ovixan® receives positive review by Nordic Authorities
Galenica AB’s new pharmaceutical product for treatment of Psoriasis and Eczema, Ovixan®, received on Thursday the 15th of December a positive review by Nordic Authorities.
Malmö-based Galenica informs that Ovixan® received approval in the decentralized procedure involving all Nordic countries, and can now proceed to national step for granting Market Authorization. Reporting countries are Sweden, Norway, Denmark, Finland and Iceland.
Galenica CEO Ronnie Wallin comments the news of approval:
"We have been looking forward to this day for many years and are very pleased to have reached this stage. What’s left is the Market Authorization from each of the Nordic Countries. However, we still have a long way to go before we reach our main goal; to be able to grant Psoriasis and Eczema patients the use of Ovixan®."
For further information, please contact:
Ronnie Wallin, CEO Galenica AB
T +46 708 21 11 22
email: Ronnie.wallin@galenica.se
Joakim Hindemith, Business Unit Director Galenica AB
T +46 722 49 71 00
email: Joakim.hindemith@galenica.se
Ämnen
- Hälsa, sjukvård, läkemedel
Kategorier
- psoriasis
- eczema
Regioner
- Utanför Sverige
About Galenica AB
Galenica is a Swedish hi-tech pharmaceutical company active in the development of new pharmaceutical products. The company, based at Medeon Science Park in Malmö, Sweden, is also well established within formulation, manufacturing and quality control of all common dosage forms. Galenica is preparing to launch the new Sales and Marketing unit to promote Ovixan®.
